Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | USP8 | P40818 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 4/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7779040 | 0.94 | L3MBTL1 (0.37) | TSHRCA2MPOSMN1; SMN2 | |
| SCHEMBL6132567 | 0.90 | KCNA3 (0.35) | TSHRSMN1; SMN2 | |
| SCHEMBL1143957 | 0.90 | SMN1; SMN2 (0.38) | TSHRSMN1; SMN2 | |
| SCHEMBL6238419 | 0.89 | JAK2 (0.33) | SMN1; SMN2 | |
| SCHEMBL6132896 | 0.89 | KDM4E (0.35) | SMN1; SMN2 | |
| SCHEMBL4813845 | 0.85 | TSHR (0.33) | TSHRCA2MPO | |
| SCHEMBL2453704 | 0.82 | DRD2 (0.46) | TSHRSMN1; SMN2 | |
| SCHEMBL757705 | 0.82 | PTPN1 (0.37) | SMN1; SMN2 | |
| SCHEMBL126227 | 0.82 | ALDH1A1 (0.34) | CA2SMN1; SMN2 | |
| SCHEMBL2449865 | 0.81 | L3MBTL1 (0.38) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 777 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4330247-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd (CN) | 2024-03-06 | — | — | EP | claimed |
| WO-2022228496-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2022-11-03 | — | — | WO | claimed |
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | claimed |
| EP-2951179-B1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2020-03-11 | — | — | EP | claimed |
| US-9708321-B2 | Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | claimed |
| CN-105121455-B | Novel triptolide derivative and preparation method and application thereof | 香港浸会大学 | 2017-06-16 | — | — | CN | claimed |
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | claimed |
| EP-2951179-A1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | Merck Patent GmbH (DE) | 2015-12-09 | — | — | EP | claimed |
| CN-102781937-B | As two (difluoromethyl) pyrazoles of sterilant | BAYER CROPSCIENCE AG (DE) | 2015-09-30 | — | — | CN | claimed |
| EP-2516426-B1 | BIS(DIFLUORMETHYL)PYRAZOLES USED AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2015-09-16 | — | — | EP | claimed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | claimed |
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | claimed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | claimed |
| CN-1281433-A | Hydroxamic acid derivatives as matrix metalloproteinase (MMP) inhibitors | PFIZER LTD (US) | 2001-01-24 | — | — | CN | claimed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | claimed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | claimed |
| EP-0367887-B1 | Herbicidal concentrate | CIBA GEIGY AG (CH) | 1994-03-30 | — | — | EP | claimed |
| US-4933000-A | Herbicidal compound concentrate | CIBA-GEIGY CORPORATION (US) | 1990-06-12 | — | — | US | claimed |
| EP-0367887-A2 | Herbicidal concentrate | CIBA-GEIGY AG (CH) | 1990-05-16 | — | — | EP | claimed |
| EP-0348343-A2 | Synergistic agent and process for selective weed control in cereals, maize and rice | CIBA-GEIGY AG (CH) | 1989-12-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | GRM4, GRIA4, GRIK4 | TSHR 839/4885CA2 2342/4885MPO 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.